Published 2023-06-01
“…Toshiyuki Koya,1 Kazuhisa Asai,2 Takashi Iwanaga,3 Yu Hara,4 Mai Takahashi,5 Naoyuki Makita,5 Nobuya Hayashi,6 Naoki Tashiro,5 Yuji Tohda7,8 1Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; 2Department of Respiratory Medicine,
Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; 3Center for General Medical Education and Clinical Training, Kindai University Faculty of Medicine, Osakasayama, Japan; 4Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan; 5Medical Department, AstraZeneca KK, Osaka, Japan; 6R&D, AstraZeneca KK, Osaka, Japan; 7Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osakasayama, Japan; 8Kinki Hokuriku Airway disease Conference (KiHAC) Group, Osakasayama, JapanCorrespondence: Toshiyuki Koya, Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-ku, Niigata, 951-8510, Japan, Tel +81 25-368-9325, Fax +81 25-368-9326, Email tkoya@med.niigata-u.ac.jpPurpose: Treatment patterns and patient characteristics are not well elucidated among Japanese patients with severe uncontrolled asthma who currently have various treatment options, including biologics. …”
Get full text
Article